Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2014 Future Medicine Ltd. Although one Millennium Development Goal target, to halt and reverse the TB epidemic, has been achieved, there were still 8.7 million new TB cases and 1.4 million deaths from TB in 2011 [1]. The rate of decline needs to increase in order to progress towards eliminating the disease and effective prophylactic vaccination is key to achieving this. The only existing licensed prophylactic TB vaccine is bacillus Calmette-Guerin, an attenuated strain of Mycobacterium bovis, which has been in use since 1920. Over the past decade, a number of novel TB vaccine candidates have been developed and many are now in clinical trials. Validated preclinical animal models of TB and immune biomarkers of protection are required to facilitate selection of which candidate vaccines should enter early-stage clinical trials, and which should progress to large-scale efficacy testing.

Original publication

DOI

10.2217/EBO.13.5752

Type

Chapter

Book title

Clinical Insights: Tuberculosis Prevention

Publication Date

01/01/2014

Pages

33 - 52